Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Medicare and Medicaid recipients can be reimbursed for the medications to treat diabetes, but currently the anti-obesity ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

April 14, 2025 Novo Nordisk warns consumers about counterfeit ... in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double ...